Table 4.

Association between prescription patterns and improving hyperphosphatemia and hypercalcemia toward the target range

Prescription PatternACa (pg/ml)Proportionb (%)PD95% CI
CinacalcetVDRA
Hyperphosphatemia (1528 sets)c
NotDecreased−1.0651.90.05−0.02 to 0.13
NotStable−0.8344.2Reference
NotIncreased−0.8042.0−0.03−0.10 to 0.04
StartingDecreased−1.5869.00.230.10–0.36
StartingStable−1.0646.20.03−0.06 to 0.11
StartingIncreased−0.8246.20.02−0.12 to 0.16
Hypercalcemia (1263 sets)d
NotDecreased−0.5342.00.05−0.03 to 0.12
NotStable−0.2235.6Reference
NotIncreased−0.2539.40.00−0.08 to 0.09
StartingDecreased−0.8957.70.170.07–0.28
StartingStable−0.6164.10.220.14–0.31
StartingIncreased−0.3148.00.10−0.02 to 0.22
  • VDRA, vitamin D receptor activator; AC, absolute change; PD, proportion difference; 95% CI, 95% confidence interval; iPTH, intact parathyrpid hormone.

  • a Means of AC between reference and outcome visits.

  • b Proportions of patients with achievement of target levels.

  • c Adjusted for age, sex, dialysis duration, intact PTH levels, calcium levels, use of calcium- or non–calcium-based phosphate binders, single-pool Kt/V, and dialysate calcium.

  • d Adjusted for age, sex, dialysis duration, intact PTH levels, phosphorus levels, use of calcium- or non–calcium-based phosphate binders, single-pool Kt/V, and dialysate calcium.